In recent years, ivosidenib (AG120), an IDH1 inhibitor, has been used in the treatment of relapsed and refractory AML[45] while many other inhibitors including Olutasidenib (FT-2102), IDH305, Vorasidenib (AG881), BAY1436032, LY3410738 and DS-1001 are currently being evaluated in Phase I/II clinical trials in patients with IDH1/2 mutant AML. Here, IDH1 is linked to acute myeloid leukemia.